Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
EIKNthis companyEikon Therapeutics, Inc. Common Stock	$5.75	-2.44×	-0.92×	0×	-3.22×	-149.8%	0.0%	0.0%	0.0%	36.9%	-61.7%	-29.0%	-0.29×	-0.51×	-404.95×	6.34×	0.0%	—	—	2	C
ARVNArvinas, Inc.	$6.51	-9.27×	1.77×	2.93×	-8.44×	-1590.9%	98.0%	-43.8%	-30.8%	-18.6%	-19.9%	-35.8%	0.02×	1.78×	0×	4.92×	0.0%	3	0.86	3	B-
BBOTBridgeBio Oncology Therapeutics Inc.	$2.16	-2.91×	0.95×	0×	-0.13×	414.3%	0.0%	0.0%	0.0%	-32.6%	-35.2%	-29.4%	0.01×	2.55×	0×	12.14×	0.0%	0	-0.72	3	B
NVCTNuvectis Pharma, Inc.	$21.01	-5.72×	8.94×	0×	-5.03×	-93.9%	0.0%	0.0%	0.0%	-143.6%	-149.8%	-9.7%	0×	1.2×	0×	2.38×	0.0%	1	17.43	1	D+
ORICORIC Pharmaceuticals, Inc.	$9.19	-5.56×	1.87×	0×	-5.33×	-96.2%	0.0%	0.0%	0.0%	-33.7%	-36.3%	-15.9%	0.03×	0.27×	0×	14.13×	0.0%	1	21.2	2	C
PRLDPrelude Therapeutics Incorporated	$3.81	-2.25×	3.25×	18.38×	-1.48×	-2.4%	85.9%	-861.3%	-819.6%	-145.0%	-114.8%	-25.3%	0.26×	0.18×	0×	1.99×	0.0%	4	-3.06	2	C
Peer median	—	-5.56×	1.87×	0×	-5.03×	-93.9%	0.0%	0.0%	0.0%	-33.7%	-36.3%	-25.3%	0.02×	1.2×	0×	4.92×	0.0%	1	0.86	2	—